Literature DB >> 30088359

Successful Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation after CARVAR Operation.

Hyungdon Kook1, Cheol Woong Yu2, Seung Hun Lee1, Haim Danenberg3, Seong Mi Park1.   

Abstract

Entities:  

Year:  2018        PMID: 30088359      PMCID: PMC6110703          DOI: 10.4070/kcj.2018.0108

Source DB:  PubMed          Journal:  Korean Circ J        ISSN: 1738-5520            Impact factor:   3.243


× No keyword cloud information.
Transcatheter aortic valve replacement (TAVR) in aortic regurgitation (AR) has not been well established, because the absence of an anchoring point such as calcification at the annulus and leaflets is known to be an obstacle to the procedure.1) A 79-year-old female patient had severe AR after a Comprehensive Aortic Root and VAlve Repair (CARVAR) operation presenting with worsening dyspnea (Supplementary Video 1). CARVAR operation is a valve sparing surgical technique for aortic diseases, consisting of annular and sinotubular junction (STJ) reduction with leaflet correction.2) For reduction and correction of aortic structures, specially designed outer strip ring is used in CARVAR procedure. However, this novel technique which had been criticized for safety issues comparing with the conventional valve replacement surgery was banned in South Korea since 2013.3) Due to high surgical risk (Society of Thoracic Surgeon's predicted risk of mortality score 14.756%) and frailty of the patient (clinical frailty scale of 6), heart team decided to proceed with the TAVR procedure. In preprocedural device selection, the perimeter of the annulus was 71.9 mm and the perimeter driven diameter was 22.9 mm in multi-slice computed tomography (CT) images. The diameter of STJ with outer ring was measured as 27 mm. We thought that 2 possible anchoring points were annulus and STJ with outer ring. Therefore, a 26 or 29 mm transcatheter heart valve seemed to be possible according to the conventional annular valve sizing because perimeter or diameter was on the gray zone. Considering TAVI for AR with no calcification at annulus, larger one would be better. In addition, considering the possibility that the upper part of the transcatheter heart valve is anchored to the 27 mm-sized CARVAR ring located in the STJ instead of annulus, a transcatheter heart valve of 29 or 31 mm is considered to be appropriate. Finally, we chose a 29 mm Evolut™ R valve instead of a larger sized transcatheter heart valve due to possible risk of device deformation by outer strip ring. Despite the absence of any calcification at the annulus and leaflets (Figure 1), a 29 mm CoreValve® Evolut™ R valve (Medtronic, Minneapolis, MN, USA) was successfully implanted at a slightly lower location than the usual position utilizing an outer ring used in CARVAR surgery as the landing zone (Figure 2, Supplementary Videos 2 and 3). Upper part between outflow and waist of 29 mm Evolut™ R valve was seated at the outer strip ring.
Figure 1

Pre-procedural CT findings. (A, B) No calcification of aortic leaflets and annulus. (C, D) Outer strip ring used in the CARVAR operation tightening the aorta.

CARVAR = Comprehensive Aortic Root and VAlve Repair; CT = computed tomography.

Figure 2

Aortogram during the TAVR procedures. (A) TAVR using the outer strip ring as an anchoring point. (B) Middle part between outflow and waist of 29 mm Evolut™ R valve was seated at the outer strip ring. Arrows indicate the location of the outer strip ring used in CARVAR operation.

CARVAR = Comprehensive Aortic Root and VAlve Repair; TAVR = transcatheter aortic valve replacement.

After TAVR procedure, the patient's dyspnea improved markedly. Echocardiography showed well-functioning transcatheter heart valve without any definite evidence of central AR or paravalvular leakage (Supplementary Video 4). N-terminal brain natriuretic peptides reduced from 10,027 to 2,708 pg/mL and cardiomegaly decreased (Figure 3).
Figure 3

Chest radiography of pre- and post-TAVR. Cardiothoracic ratio decreased from 67.4% to 57.2%.

TAVR = transcatheter aortic valve replacement.

These images highlight the importance of adequate anchoring points when performing TAVR for AR.4)5)
  5 in total

1.  Transcatheter Options for the Treatment of Noncalcified Aortic Regurgitation.

Authors:  John G Webb; Nay Htun
Journal:  JACC Cardiovasc Interv       Date:  2015-11-18       Impact factor: 11.195

2.  Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation.

Authors:  David A Roy; Ulrich Schaefer; Victor Guetta; David Hildick-Smith; Helge Möllmann; Nicholas Dumonteil; Thomas Modine; Johan Bosmans; Anna Sonia Petronio; Neil Moat; Axel Linke; Cesar Moris; Didier Champagnac; Radoslaw Parma; Andrzej Ochala; Diego Medvedofsky; Tiffany Patterson; Felix Woitek; Marjan Jahangiri; Jean-Claude Laborde; Stephen J Brecker
Journal:  J Am Coll Cardiol       Date:  2013-02-20       Impact factor: 24.094

3.  Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry.

Authors:  Danny Dvir; John Webb; Stephen Brecker; Sabine Bleiziffer; David Hildick-Smith; Antonio Colombo; Fleur Descoutures; Christian Hengstenberg; Neil E Moat; Raffi Bekeredjian; Massimo Napodano; Luca Testa; Thierry Lefevre; Victor Guetta; Henrik Nissen; José-María Hernández; David Roy; Rui C Teles; Amit Segev; Nicolas Dumonteil; Claudia Fiorina; Michael Gotzmann; Didier Tchetche; Mohamed Abdel-Wahab; Federico De Marco; Andreas Baumbach; Jean-Claude Laborde; Ran Kornowski
Journal:  Circulation       Date:  2012-10-10       Impact factor: 29.690

4.  Safety of comprehensive aortic root and valve repair surgery: a retrospective outcomes research by national evidence-based health care collaborating agency, Korea.

Authors:  Jong-Myon Bae; Eunhee Shin; Dae Seog Heo
Journal:  Korean Circ J       Date:  2012-11-28       Impact factor: 3.243

5.  Novel technique of aortic valvuloplasty.

Authors:  Shee Young Hahm; Suk Jung Choo; Jae Won Lee; Joon Beom Seo; Tae Hwan Lim; Jae Kwan Song; Je Kyoun Shin; Meong Gun Song
Journal:  Eur J Cardiothorac Surg       Date:  2006-02-23       Impact factor: 4.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.